Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salbutamol + budesonide is a fixed-dose combination inhalation medication used for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in adults. It combines two active ingredients: salbutamol (also known as albuterol), a short-acting beta2-adrenergic agonist bronchodilator that relaxes airway smooth muscle, and budesonide, an inhaled corticosteroid that reduces inflammation in the airways. This combination is notable for being the first product containing an inhaled corticosteroid approved by the FDA as a reliever (rescue) therapy rather than solely as a controller medication for asthma. The drug is administered via oral inhalation using a metered-dose inhaler[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salbutamol + budesonide.